CoinCentral
TLDR Q1 adjusted EPS of $2.22 beat the $2.15 estimate; revenue of $15.53B exceeded $15.39B forecast Keytruda sales rose 6% to $7.21B but missed expectations due to U.S. wholesaler timing Gardasil revenue dropped 40% amid weak China demand New drugs like Winrevair and Capvaxive posted strong growth Merck cut full-year EPS forecast slightly to $8.82–$8.97 […]
The post Merck (MRK) Stock: Q125 Beats Expectations but Guidance Cut Amid China Weakness…
Read More
Merck (MRK) Stock: Q125 Beats Expectations but Guidance Cut Amid China Weakness, Tariff Concerns
Yasmin Werner
02:24
TLDR Q1 adjusted EPS of $2.22 beat the $2.15 estimate; revenue of $15.53B exceeded $15.39B forecast Keytruda sales rose 6% to $7.21B but missed expectations due to U.S. wholesaler timing Gardasil revenue dropped 40% amid weak China demand New drugs like Winrevair and Capvaxive posted strong growth Merck cut full-year EPS forecast slightly to $8.82–$8.97
